Golf legend John Daly makes light of recent health scares: ‘I've only been dead 11 times'
John Daly has admittedly lived an interesting life both on and off the course.
Earlier this week, ahead of The Galleri Classic, the two-time major winner reflected on his lengthy career when shown a picture of his rookie tour card from 1992.
"I didn't think I'd been out here for three decades," Daly said in a video shared by the PGA Tour Champions. "I've only been dead 11 times. I'm like Lazarus. I just keep coming back from the dead.
"That's when I could actually play the game."
He made the comment about his health about two months after he underwent emergency surgery on his hand. He shared a post from his hospital bed in January, adding that the surgery was a success and that he would "be back playing in no time!"
He returned this month in time for the Champions Tour's Hoag Classic in California.
"It's been a little brutal, but the hand's about 80%," he said at the time in a video, via ESPN. Daly revealed he has undergone 16 surgeries in the last four years due to tangled tendons.
In a recent podcast appearance, Daly also opened up about being diagnosed with bladder cancer.
"It was scary," he said during an appearance on the "Like a Farmer Podcast."
"I was peeing blood, pukin' blood. ... I thought my back was killing me, and I didn't know. And I went in Little Rock, got a checkup and everything on my back and then, was it a neurologist? Doctor saw it and said, 'You gotta come back.'"
He underwent surgery and has been in remission for four years.
Despite all his health setbacks, Daly had a positive message about life for his younger self when looking back at his rookie picture.
"Hey, great life."
Follow Fox News Digital's sports coverage on X, and subscribe to the Fox News Sports Huddle newsletter.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Common menopause medication might prevent breast cancer while treating hot flashes
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, "significantly reduced" breast tissue cell growth, which is a major indicator of cancer progression. A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. Prostate Cancer Drug Now Available To More Patients With Aggressive Form Of Disease This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Read On The Fox News App Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. "The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo," Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. Experimental Women's Cancer Drug Boosts Survival Rates In Notable Study Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. "This would be expected, as the drug is FDA-approved to treat hot flashes." Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The findings are preliminary and have not yet been published in a medical journal. "What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer," said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced "high-risk lesions" — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. "These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options," the release stated. The researchers said they are "encouraged" by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. "Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure," Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. "While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk," she told Fox News Digital. Click Here To Sign Up For Our Health Newsletter Kabraji also noted that the study focused on reducing levels of one specific protein, "which does not always predict reduced recurrence of breast cancer." "This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer," she noted. "Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention." For more Health articles, visit Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. "Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms," she article source: Common menopause medication might prevent breast cancer while treating hot flashes
UPI
9 hours ago
- UPI
ESPN's Jay Harris diagnosed with prostate cancer
ESPN host Jay Harris explained that his father had prostate cancer, and as a Black man, he knows the disease carries a higher risk. Photo courtesy of ESPN June 6 (UPI) -- Longtime ESPN Sports Center anchor Jay Harris has been diagnosed with prostate cancer and is scheduled to have surgery Tuesday. Harris, 60, wrote about his experience in an essay posted Thursday on ESPN's Front Row website. He said he got the news "over a month ago," NBC News reported. "It's jarring news for sure, yet unfortunately, it's not unexpected, given my family history and demographic," he wrote. Harris explained that his father had prostate cancer, and as a Black man, he knows the disease carries a higher risk. "I'm 60. It's something I've always been cognizant of, and my doctor and I talk about it every annual visit," he continued. "And I'm sharing it all with my 26-year-old son. Maybe I'm oversharing at times -- lol -- but he needs to know." The good news, Harris added, is that his PET scan showed no signs that the cancer has spread. Depending on what doctors find during the procedure, he hopes to return to work "in a month or so." "My goal in sharing this is to join the many others who also want to normalize this conversation and hopefully provide a bit of guidance and preparation, just as it has been offered to me," he wrote. About 1 in 8 men are diagnosed with prostate cancer in their lifetime, according to the American Cancer Society. It's the second-leading cause of cancer death among men in the United States. Most cases are diagnosed in men age 65 and older, and Black men are more likely to get it and die from it, the ACS notes. If caught early, many forms of prostate cancer have a five-year survival rate above 99%, according to the ACS. Harris said one of the most meaningful parts of the experience so far has been the support and stories that others have shared, NBC News reported. "Whenever I've mentioned my diagnosis, invariably I've gotten, 'Oh, my cousin did the radiation,' or 'My father had the surgery,' or 'My uncle went through that years ago. Do you want me to ask him to call you?' " Harris wrote. More information The American Cancer Society explains which men need to be screened for prostate cancer. Copyright © 2025 HealthDay. All rights reserved.
USA Today
12 hours ago
- USA Today
There is a medical reason why Tyrese Haliburton sounds like he has two different voices
There is a medical reason why Tyrese Haliburton sounds like he has two different voices Indiana Pacers star guard Tyrese Haliburton has continued his heroic postseason run, but if you listen to him talk about it, you may notice something. Haliburton, who represented Team USA during the Paris Olympics, occasionally sounds like he has two entirely different voices. Just press play on this clip of Haliburton talking about the improbable comeback that Indiana had against the Oklahoma City Thunder in Game of the NBA Finals. In the beginning of the interview on national TV, Haliburton is speaking with a slightly deeper voice. Then (ironically) right as he said the words "why would that change" later in the conversation, his voice suddenly had a much higher pitch. More: Tyrese Haliburton and the Pacers keep pulling off the impossible It happened during his postgame press conference as well: This is something that some fans noticed when Haliburton appeared on The Young Man and the Three with JJ Redick. Then it happened against before the 2024 NBA All-Star Game hosted in Indiana as well: Haliburton has acknowledged that this is indeed something that happens to him. It is something he has talked about with ESPN's Pat McAfee. Here is what what he says: "I do. People say that all the time ... I never catch it. I watch podcasts after and I'm like, 'Dang, my voice changed.' I didn't do that on purpose. It just happened. It just happens that way naturally sometimes." Haliburton added that he feels he has no control over it, and it's something that just happens to him. So why exactly does that happen? Brianna Williams reached out to Dr. Michael M. Johns from USC's Voice Center, and he provided a possible explanation (via ESPN): "Vocalization is a lot like athletics; people don't think of it that way because it happens naturally," Dr. Johns told ESPN. "It's like putting aluminum foil on a guitar string; the sound changes when the vibration is irregular." Regarding Haliburton's voice, Dr. Johns observed: "When you listen to Tyrese's voice, there's a rough quality to it, and that would likely be a change of what's happening at the vocal cords, like that 'tinfoil on the guitar string' analogy." He speculated that Haliburton might be compensating for vocal fatigue by changing his resonance, shifting the shape of his vocal tract or resonator. "Athletes are using their voice a lot, and they're using their voice loudly," Dr. Johns explained. "They're hollering across the court. There's a huge amount of noise around them. They've got to be heard over that noise. And so they, like other vocal athletes, can develop some injury to their vocal folds, vocal nodules, or vocal swelling that can cause some rough quality to the voice." This is fascinating and something that makes Haliburton very unique.
